FI971420A - Förfarande för behandling av diabetes mellitus med användning av KGF - Google Patents

Förfarande för behandling av diabetes mellitus med användning av KGF Download PDF

Info

Publication number
FI971420A
FI971420A FI971420A FI971420A FI971420A FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A
Authority
FI
Finland
Prior art keywords
kgf
diabetes mellitus
treating diabetes
mammals
pharmaceutical compositions
Prior art date
Application number
FI971420A
Other languages
English (en)
Finnish (fi)
Other versions
FI971420A0 (sv
Inventor
Sharon Lea Aukerman
Glenn Frencis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI971420A publication Critical patent/FI971420A/sv
Publication of FI971420A0 publication Critical patent/FI971420A0/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI971420A 1994-10-13 1997-04-04 Förfarande för behandling av diabetes mellitus med användning av KGF FI971420A0 (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number Publication Date
FI971420A true FI971420A (sv) 1997-04-04
FI971420A0 FI971420A0 (sv) 1997-04-04

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971420A FI971420A0 (sv) 1994-10-13 1997-04-04 Förfarande för behandling av diabetes mellitus med användning av KGF
FI971536A FI120040B (sv) 1994-10-13 1997-04-11 Analoger av keratinocytväxtfaktorn

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI971536A FI120040B (sv) 1994-10-13 1997-04-11 Analoger av keratinocytväxtfaktorn

Country Status (23)

Country Link
EP (2) EP0804479B1 (sv)
JP (2) JP4426646B2 (sv)
KR (1) KR100278597B1 (sv)
CN (1) CN1168678A (sv)
AT (2) ATE342278T1 (sv)
AU (1) AU3707795A (sv)
BG (2) BG101392A (sv)
BR (2) BR9509269A (sv)
CA (2) CA2202075C (sv)
CZ (3) CZ297329B6 (sv)
DE (2) DE69530403T2 (sv)
DK (2) DK0785948T3 (sv)
EE (2) EE03975B1 (sv)
ES (2) ES2196082T3 (sv)
FI (2) FI971420A0 (sv)
HU (2) HUT78050A (sv)
NO (2) NO318761B1 (sv)
NZ (2) NZ505502A (sv)
PL (2) PL182888B1 (sv)
PT (2) PT804479E (sv)
SI (2) SI0804479T1 (sv)
SK (2) SK284534B6 (sv)
WO (2) WO1996011949A2 (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
SK153295A3 (en) 1993-06-29 1996-11-06 Chiron Corp A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
EP0785949B1 (en) * 1994-10-13 2003-05-02 Amgen Inc. Method for purifying keratinocyte growth factors
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
WO1996034017A1 (en) * 1995-04-27 1996-10-31 Coöperatie Suiker Unie U.A. Inulin derivatives
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
CA2269077C (en) * 1996-10-15 2004-04-06 Amgen Inc. Keratinocyte growth factor-2 products
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
NZ505324A (en) 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
CA2437270A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified keratinocyte growth factor (kgf) with reduced immunogenicity
WO2003016505A2 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
CN101084008B (zh) 2004-12-15 2013-04-10 比奥维特罗姆股份公开公司 角质形成细胞生长因子的治疗制剂
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd reg蛋白質
WO1990000877A1 (en) * 1988-07-27 1990-02-08 Marjan International Pty Ltd Carpet stretcher
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 bFGFムテインおよびその製造法
CN1064710C (zh) * 1993-03-26 2001-04-18 安姆根有限公司 角质细胞生长因子的治疗应用
SK153295A3 (en) * 1993-06-29 1996-11-06 Chiron Corp A truncated keratinocyte growth factor (kgf) having increased biological activity
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
WO1995003831A1 (en) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
BR9509329A (pt) 1997-10-14
CN1168678A (zh) 1997-12-24
CA2202075C (en) 2003-12-09
CZ105097A3 (cs) 1998-10-14
PL319784A1 (en) 1997-08-18
PT804479E (pt) 2007-02-28
SK45597A3 (en) 1999-02-11
JP4426646B2 (ja) 2010-03-03
NO971566D0 (no) 1997-04-04
SI0804479T1 (sl) 2006-12-31
NO971568L (no) 1997-06-12
SI0785948T1 (en) 2003-08-31
EE9700081A (et) 1997-10-15
DE69535264T2 (de) 2007-02-01
EE03975B1 (et) 2003-02-17
HU226168B1 (en) 2008-05-28
ES2273338T3 (es) 2007-05-01
ATE237633T1 (de) 2003-05-15
SK284534B6 (sk) 2005-06-02
JPH10507193A (ja) 1998-07-14
BG101408A (en) 1997-12-30
FI971536A (sv) 1997-06-09
CZ297328B6 (cs) 2006-11-15
HUT78050A (hu) 1999-07-28
NO318761B1 (no) 2005-05-02
JPH10507080A (ja) 1998-07-14
FI120040B (sv) 2009-06-15
ES2196082T3 (es) 2003-12-16
WO1996011950A1 (en) 1996-04-25
NO971568D0 (no) 1997-04-04
BR9509269A (pt) 1997-12-23
NO971566L (no) 1997-04-14
SK43197A3 (en) 1999-03-12
KR100278597B1 (ko) 2001-01-15
HUT78058A (hu) 1999-07-28
DE69535264D1 (de) 2006-11-23
ATE342278T1 (de) 2006-11-15
EE9700225A (et) 1998-02-16
CA2201940C (en) 2009-05-12
CZ297329B6 (cs) 2006-11-15
EP0785948A1 (en) 1997-07-30
FI971536A0 (sv) 1997-04-11
PL320484A1 (en) 1997-09-29
EP0804479B1 (en) 2006-10-11
BG63167B1 (bg) 2001-05-31
DK0804479T3 (da) 2007-01-29
DK0785948T3 (da) 2003-08-04
NZ335109A (en) 2000-08-25
DE69530403T2 (de) 2003-10-30
WO1996011949A3 (en) 1996-12-12
JP4216329B2 (ja) 2009-01-28
EP0785948B1 (en) 2003-04-16
WO1996011949A2 (en) 1996-04-25
CZ98197A3 (cs) 1998-11-11
FI971420A0 (sv) 1997-04-04
AU681546B2 (en) 1997-08-28
BG101392A (en) 1997-10-31
PT785948E (pt) 2003-09-30
PL182888B1 (pl) 2002-03-29
EP0804479A1 (en) 1997-11-05
AU3707795A (en) 1996-05-06
CA2202075A1 (en) 1996-04-25
NZ505502A (en) 2005-01-28
AU3708395A (en) 1996-05-06
DE69530403D1 (de) 2003-05-22
CA2201940A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
FI971420A (sv) Förfarande för behandling av diabetes mellitus med användning av KGF
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
AU2209500A (en) Inhibitors of alpha4beta1 mediated cell adhesion
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
FR2491334B1 (sv)
AU5323396A (en) Methods of treating inflammation and compositions therefor
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
GB9410639D0 (en) Method of improving fertilization
PT821588E (pt) Levobupivacaina e sua utilizacao como anestesico em mulheres gravidas
SE9400524D0 (sv) Energipreparat
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
ATE315583T1 (de) Analoge des thymosin alpha 1
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці